Teva calls off CGRP drug discovery and development pact, returns preclinical asset to Sosei
A struggling Teva has pulled out of a CGRP migraine drug discovery and development pact with the G protein coupled receptor experts at Sosei, just …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
